CoChat
Sign Up
Cited by 215Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchRedox biology and oxidative stress

Oxidatively modified proteins in Alzheimer’s disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis

Open access
Sultana, Rukhsana, Perluigi, Marzia, Butterfield, D. Allan·2009·Acta Neuropathologica
DOI 10.1007/s00401-009-0517-0PMC PMC2818870
Open this paper in CoChat — free account

Abstract

Oxidative stress has been implicated in the pathogenesis of a number of diseases including Alzheimer's disease (AD). The oxidative stress hypothesis of AD pathogenesis, in part, is based on beta-amyloid peptide (Abeta)-induced oxidative stress in both in vitro and in vivo studies. Oxidative modification of the protein may induce structural changes in a protein that might lead to its functional impairment. A number of oxidatively modified brain proteins were identified using redox proteomics in AD, mild cognitive impairment (MCI) and Abeta models of AD, which support a role of Abeta in the alteration of a number of biochemical and cellular processes such as energy metabolism, protein degradation, synaptic function, neuritic growth, neurotransmission, cellular defense system, long term potentiation involved in formation of memory, etc. All the redox proteomics-identified brain proteins fit well with the appearance of the three histopathological hallmarks of AD, i.e., synapse loss, amyloid plaque formation and neurofibrillary tangle formation and suggest a direct or indirect association of the identified proteins with the pathological and/or biochemical alterations in AD. Further, Abeta models of AD strongly support the notion that oxidative stress induced by Abeta may be a driving force in AD pathogenesis. Studies conducted on arguably the earliest stage of AD, MCI, may elucidate the mechanism(s) leading to AD pathogenesis by identifying early markers of the disease, and to develop therapeutic strategies to slow or prevent the progression of AD. In this review, we summarized our findings of redox proteomics identified oxidatively modified proteins in AD, MCI and AD models.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-009-0517-0

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • AI-based analytical methods are increasingly used for enrichment, site identification, and functional network modeling of PTMs.

    “Given the complexity and low abundance of many PTMs, AI-based analytical methods are increasingly used for enrichment, site identification, and functional network modeling139,169,178,179.”

    From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [178]

    The Redox proteomics section describes gel electrophoresis, mass spectrometry, Western blotting, and image-analysis software for identifying modified proteins; it also notes difficulty detecting low-abundance proteins. Searches for AI or machine-learning methods, enrichment, modification-site identification, and functional network modeling found no passage addressing the attributed claim. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 159

  1. [1]Abdul HM Calabrese V Calvani M Butterfield DA Acetyl-l-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1–42-mediated oxidative stress and neurotoxicity: implications for Alzheimer’s disease J Neurosci Res 2006 84 398 408 doi: 10.1002/jnr.20877 16634066 · DOI
  2. [2]Aksenova M Butterfield DA Zhang SX Underwood M Geddes JW Increased protein oxidation and decreased creatine kinase BB expression and activity after spinal cord contusion injury J Neurotrauma 2002 19 491 502 doi: 10.1089/08977150252932433 11990354 · DOI
  3. [3]Anantharaman M Tangpong J Keller JN Murphy MP Markesbery WR Kiningham KK St Clair DK Beta-amyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer’s disease Am J Pathol 2006 168 1608 1618 doi: 10.2353/ajpath.2006.051223 16651627 PMC1606606 · DOI
  4. [4]Ansari MA Joshi G Huang Q Opii WO Abdul HM Sultana R Butterfield DA In vivo administration of D609 leads to protection of subsequently isolated gerbil brain mitochondria subjected to in vitro oxidative stress induced by amyloid beta-peptide and other oxidative stressors: relevance to Alzheimer’s disease and other oxidative stress-related neurodegenerative disorders Free Radic Biol Med 2006 41 1694 1703 doi: 10.1016/j.freeradbiomed.2006.09.002 17145558 PMC1827074 · DOI
  5. [5]Bader Lange ML Cenini G Piroddi M Abdul HM Sultana R Galli F Memo M Butterfield DA Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease Neurobiol Dis 2008 29 456 464 18077176 PMC2292396
  6. [6]Beckman JS Oxidative damage and tyrosine nitration from peroxynitrite Chem Res Toxicol 1996 9 836 844 doi: 10.1021/tx9501445 8828918 · DOI
  7. [7]Biroccio A Del Boccio P Panella M Bernardini S Di Ilio C Gambi D Stanzione P Sacchetta P Bernardi G Martorana A Federici G Stefani A Urbani A Differential post-translational modifications of transthyretin in Alzheimer’s disease: a study of the cerebral spinal fluid Proteomics 2006 6 2305 2313 doi: 10.1002/pmic.200500285 16552785 · DOI
  8. [8]Boyd-Kimball D Castegna A Sultana R Poon HF Petroze R Lynn BC Klein JB Butterfield DA Proteomic identification of proteins oxidized by Abeta(1–42) in synaptosomes: implications for Alzheimer’s disease Brain Res 2005 1044 206 215 doi: 10.1016/j.brainres.2005.02.086 15885219 · DOI
  9. [10]Boyd-Kimball D Sultana R Mohmmad-Abdul H Butterfield DA Neurotoxicity and oxidative stress in D1M-substituted Alzheimer’s A beta(1–42): relevance to N-terminal methionine chemistry in small model peptides Peptides 2005 26 665 673 doi: 10.1016/j.peptides.2004.11.001 15752582 · DOI
  10. [11]Boyd-Kimball D Sultana R Poon HF Lynn BC Casamenti F Pepeu G Klein JB Butterfield DA Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1–42) into rat brain: implications for Alzheimer’s disease Neuroscience 2005 132 313 324 doi: 10.1016/j.neuroscience.2004.12.022 15802185 · DOI
  11. [12]Boyd-Kimball D Sultana R Poon HF Mohmmad-Abdul H Lynn BC Klein JB Butterfield DA Gamma-glutamylcysteine ethyl ester protection of proteins from Abeta(1–42)-mediated oxidative stress in neuronal cell culture: a proteomics approach J Neurosci Res 2005 79 707 713 doi: 10.1002/jnr.20393 15672443 · DOI
  12. [13]Brunelle P Rauk A The radical model of Alzheimer’s disease: specific recognition of Gly29 and Gly33 by Met35 in a beta-sheet model of Abeta: an ONIOM study J Alzheimers Dis 2002 4 283 289 12446930
  13. [15]Butterfield DA beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer’s disease Chem Res Toxicol 1997 10 495 506 doi: 10.1021/tx960130e 9168246 · DOI · Paper page
  14. [16]Butterfield DA Abdul HM Newman S Reed T Redox proteomics in some age-related neurodegenerative disorders or models thereof NeuroRx 2006 3 344 357 doi: 10.1016/j.nurx.2006.05.003 16815218 PMC3593385 · DOI
  15. [17]Butterfield DA Boyd-Kimball D Amyloid beta-peptide(1–42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain Brain Pathol 2004 14 426 432 15605990 PMC8096022
  16. [18]Butterfield DA Boyd-Kimball D The critical role of methionine 35 in Alzheimer’s amyloid beta-peptide (1–42)-induced oxidative stress and neurotoxicity Biochim Biophys Acta 2005 1703 149 156 15680223
  17. [19]Butterfield DA Boyd-Kimball D Castegna A Proteomics in Alzheimer’s disease: insights into potential mechanisms of neurodegeneration J Neurochem 2003 86 1313 1327 doi: 10.1046/j.1471-4159.2003.01948.x 12950441 · DOI
  18. [20]Butterfield DA Castegna A Lauderback CM Drake J Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death Neurobiol Aging 2002 23 655 664 doi: 10.1016/S0197-4580(01)00340-2 12392766 · DOI
  19. [21]Butterfield DA Drake J Pocernich C Castegna A Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid beta-peptide Trends Mol Med 2001 7 548 554 doi: 10.1016/S1471-4914(01)02173-6 11733217 · DOI · Paper page
  20. [22]Butterfield DA Gnjec A Poon HF Castegna A Pierce WM Klein JB Martins RN Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer’s disease: an initial assessment J Alzheimers Dis 2006 10 391 397 17183150
  21. [23]Butterfield DA Hensley K Cole P Subramaniam R Aksenov M Aksenova M Bummer PM Haley BE Carney JM Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer’s disease J Neurochem 1997 68 2451 2457 9166739
  22. [24]Butterfield DA Kanski J Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins Mech Ageing Dev 2001 122 945 962 doi: 10.1016/S0047-6374(01)00249-4 11348660 · DOI
  23. [25]Butterfield DA Lauderback CM Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress Free Radic Biol Med 2002 32 1050 1060 doi: 10.1016/S0891-5849(02)00794-3 12031889 · DOI
  24. [26]Butterfield DA Mohmmad-Abdul H Opii W Newman SF Joshi G Ansari MA Sultana R Role of Pin1 in Alzheimer’s disease J Neurochem 2006 98 1699 1706 doi: 10.1111/j.1471-4159.2006.03995.x 16945100 · DOI
  25. [28]Butterfield DA Reed T Newman SF Sultana R Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer’s disease and mild cognitive impairment Free Radic Biol Med 2007 43 658 677 doi: 10.1016/j.freeradbiomed.2007.05.037 17664130 PMC2031860 · DOI · Paper page
  26. [30]Butterfield DA Stadtman ER Protein Oxidation processes in aging brain Adv Cell Aging Gerontol 1997 2 161 191 doi: 10.1016/S1566-3124(08)60057-7 · DOI · Paper page
  27. [31]Carney JM Starke-Reed PE Oliver CN Landum RW Cheng MS Wu JF Floyd RA Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-alpha-phenylnitrone Proc Natl Acad Sci USA 1991 88 3633 3636 doi: 10.1073/pnas.88.9.3633 1673789 PMC51506 · DOI
  28. [32]Castegna A Aksenov M Aksenova M Thongboonkerd V Klein JB Pierce WM Booze R Markesbery WR Butterfield DA Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1 Free Radic Biol Med 2002 33 562 571 doi: 10.1016/S0891-5849(02)00914-0 12160938 · DOI · Paper page
  29. [33]Castegna A Aksenov M Thongboonkerd V Klein JB Pierce WM Booze R Markesbery WR Butterfield DA Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71 J Neurochem 2002 82 1524 1532 doi: 10.1046/j.1471-4159.2002.01103.x 12354300 · DOI
  30. [34]Castegna A Lauderback CM Mohmmad-Abdul H Butterfield DA Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer’s disease Brain Res 2004 1004 193 197 doi: 10.1016/j.brainres.2004.01.036 15033435 · DOI
  31. [35]Castegna A Thongboonkerd V Klein JB Lynn B Markesbery WR Butterfield DA Proteomic identification of nitrated proteins in Alzheimer’s disease brain J Neurochem 2003 85 1394 1401 doi: 10.1046/j.1471-4159.2003.01786.x 12787059 · DOI
  32. [36]Cenini G Sultana R Memo M Butterfield DA Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer’s disease J Cell Mol Med 2008 12 987 994 doi: 10.1111/j.1582-4934.2008.00163.x 18494939 PMC4401131 · DOI · Paper page
  33. [38]Chertkow H Bergman H Schipper HM Gauthier S Bouchard R Fontaine S Clarfield AM Assessment of suspected dementia Can J Neurol Sci 2001 28 Suppl 1 S28 S41 11237308
  34. [39]Choi J Levey AI Weintraub ST Rees HD Gearing M Chin LS Li L Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson’s and Alzheimer’s diseases J Biol Chem 2004 279 13256 13264 doi: 10.1074/jbc.M314124200 14722078 · DOI · Paper page
  35. [40]Choi J Rees HD Weintraub ST Levey AI Chin LS Li L Oxidative modifications and aggregation of Cu, Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases J Biol Chem 2005 280 11648 11655 doi: 10.1074/jbc.M414327200 15659387 · DOI
  36. [42]Coleman PD Flood DG Neuron numbers and dendritic extent in normal aging and Alzheimer’s disease Neurobiol Aging 1987 8 521 545 doi: 10.1016/0197-4580(87)90127-8 3323927 · DOI · Paper page
  37. [43]Cotman CW Head E Muggenburg BA Zicker S Milgram NW Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction Neurobiol Aging 2002 23 809 818 doi: 10.1016/S0197-4580(02)00073-8 12392784 · DOI
  38. [44]Coyle JT Price DL DeLong MR Alzheimer’s disease: a disorder of cortical cholinergic innervation Science 1983 219 1184 1190 doi: 10.1126/science.6338589 6338589 · DOI
  39. [45]Crouch PJ Barnham KJ Duce JA Blake RE Masters CL Trounce IA Copper-dependent inhibition of cytochrome c oxidase by Abeta(1–42) requires reduced methionine at residue 35 of the Abeta peptide J Neurochem 2006 99 226 236 doi: 10.1111/j.1471-4159.2006.04050.x 16987248 · DOI
  40. [46]Cummings BJ Head E Ruehl W Milgram NW Cotman CW The canine as an animal model of human aging and dementia Neurobiol Aging 1996 17 259 268 doi: 10.1016/0197-4580(95)02060-8 8744407 · DOI
  41. [47]Cutler RG Kelly J Storie K Pedersen WA Tammara A Hatanpaa K Troncoso JC Mattson MP Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease Proc Natl Acad Sci USA 2004 101 2070 2075 doi: 10.1073/pnas.0305799101 14970312 PMC357053 · DOI
  42. [49]Dalle-Donne I Scaloni A Giustarini D Cavarra E Tell G Lungarella G Colombo R Rossi R Milzani A Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics Mass Spectrom Rev 2005 24 55 99 doi: 10.1002/mas.20006 15389864 · DOI
  43. [50]Davies MJ Fu S Wang H Dean RT Stable markers of oxidant damage to proteins and their application in the study of human disease Free Radic Biol Med 1999 27 1151 1163 doi: 10.1016/S0891-5849(99)00206-3 10641706 · DOI · Paper page
  44. [51]Demuro A Mina E Kayed R Milton SC Parker I Glabe CG Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers J Biol Chem 2005 280 17294 17300 doi: 10.1074/jbc.M500997200 15722360 · DOI
  45. [52]Ding Q Markesbery WR Cecarini V Keller JN Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer’s disease Neurochem Res 2006 31 705 710 doi: 10.1007/s11064-006-9071-5 16770743 · DOI · Paper page
  46. [53]Ding Q Markesbery WR Chen Q Li F Keller JN Ribosome dysfunction is an early event in Alzheimer’s disease J Neurosci 2005 25 9171 9175 doi: 10.1523/JNEUROSCI.3040-05.2005 16207876 PMC6725754 · DOI · Paper page
  47. [54]Drake J Link CD Butterfield DA Oxidative stress precedes fibrillar deposition of Alzheimer’s disease amyloid beta-peptide (1–42) in a transgenic Caenorhabditis elegans model Neurobiol Aging 2003 24 415 420 doi: 10.1016/S0197-4580(02)00225-7 12600717 · DOI · Paper page
  48. [55]Dyrks T Dyrks E Hartmann T Masters C Beyreuther K Amyloidogenicity of beta A4 and beta A4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation J Biol Chem 1992 267 18210 18217 1517249
  49. [56]Esterbauer H Schaur RJ Zollner H Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes Free Radic Biol Med 1991 11 81 128 doi: 10.1016/0891-5849(91)90192-6 1937131 · DOI · Paper page
  50. [57]Farooqui AA Horrocks LA Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly Neuroscientist 2006 12 245 260 doi: 10.1177/1073858405285923 16684969 · DOI
  51. [58]Ferl RJ 14-3-3 proteins and signal transduction Annu Rev Plant Physiol Plant Mol Biol 1996 47 49 73 doi: 10.1146/annurev.arplant.47.1.49 15012282 · DOI
  52. [59]Fisher A Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer’s disease Neurotherapeutics 2008 5 433 442 doi: 10.1016/j.nurt.2008.05.002 18625455 PMC5084245 · DOI
  53. [60]Fisher A Muscarinic receptor agonists in Alzheimer’s disease: more than just symptomatic treatment? CNS Drugs 1999 123 197 214 doi: 10.2165/00023210-199912030-00004 · DOI
  54. [61]Geula C Nagykery N Nicholas A Wu CK Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease J Neuropathol Exp Neurol 2008 67 309 318 doi: 10.1097/NEN.0b013e31816a1df3 18379437 PMC3243760 · DOI
  55. [62]Giovannini MG Scali C Prosperi C Bellucci A Vannucchi MG Rosi S Pepeu G Casamenti F Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway Neurobiol Dis 2002 11 257 274 doi: 10.1006/nbdi.2002.0538 12505419 · DOI
  56. [63]Gong B Cao Z Zheng P Vitolo OV Liu S Staniszewski A Moolman D Zhang H Shelanski M Arancio O Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory Cell 2006 126 775 788 doi: 10.1016/j.cell.2006.06.046 16923396 · DOI
  57. [64]Gothel SF Marahiel MA Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts Cell Mol Life Sci 1999 55 423 436 doi: 10.1007/s000180050299 10228556 PMC11146858 · DOI
  58. [67]Hamdane M Dourlen P Bretteville A Sambo AV Ferreira S Ando K Kerdraon O Begard S Geay L Lippens G Sergeant N Delacourte A Maurage CA Galas MC Buee L Pin1 allows for differential Tau dephosphorylation in neuronal cells Mol Cell Neurosci 2006 32 155 160 doi: 10.1016/j.mcn.2006.03.006 16697218 · DOI
  59. [69]Head E Callahan H Muggenburg BA Cotman CW Milgram NW Visual-discrimination learning ability and beta-amyloid accumulation in the dog Neurobiol Aging 1998 19 415 425 doi: 10.1016/S0197-4580(98)00084-0 9880044 · DOI
  60. [70]Head E Torp R Insights into Abeta and presenilin from a canine model of human brain aging Neurobiol Dis 2002 9 1 10 doi: 10.1006/nbdi.2002.0476 11848680 · DOI
  61. [72]Holzer M Gartner U Stobe A Hartig W Gruschka H Bruckner MK Arendt T Inverse association of Pin1 and tau accumulation in Alzheimer’s disease hippocampus Acta Neuropathol 2002 104 471 481 12410395
  62. [73]Ischiropoulos H al-Mehdi AB Peroxynitrite-mediated oxidative protein modifications FEBS Lett 1995 364 279 282 doi: 10.1016/0014-5793(95)00307-U 7758583 · DOI
  63. [74]Joshi G Perluigi M Sultana R Agrippino R Calabrese V Butterfield DA In vivo protection of synaptosomes by ferulic acid ethyl ester (FAEE) from oxidative stress mediated by 2,2-azobis(2-amidino-propane)dihydrochloride (AAPH) or Fe(2+)/H(2)O(2): insight into mechanisms of neuroprotection and relevance to oxidative stress-related neurodegenerative disorders Neurochem Int 2006 48 318 327 doi: 10.1016/j.neuint.2005.11.006 16386335 · DOI
  64. [75]Joshi G Sultana R Perluigi M Allan Butterfield D In vivo protection of synaptosomes from oxidative stress mediated by Fe2+/H2O2 or 2, 2-azobis-(2-amidinopropane) dihydrochloride by the glutathione mimetic tricyclodecan-9-yl-xanthogenate Free Radic Biol Med 2005 38 1023 1031 doi: 10.1016/j.freeradbiomed. 2004.12.027 15780760 · DOI
  65. [76]Kanski J Aksenova M Schoneich C Butterfield DA Sub-stitution of isoleucine-31 by helical-breaking proline abolishes oxidative stress and neurotoxic properties of Alzheimer’s amyloid beta-peptide Free Radic Biol Med 2002 32 1205 1211 doi: 10.1016/S0891-5849(02)00821-3 12031904 · DOI
  66. [77]Kanski J Varadarajan S Aksenova M Butterfield DA Role of glycine-33 and methionine-35 in Alzheimer’s amyloid beta-peptide 1–42-associated oxidative stress and neurotoxicity Biochim Biophys Acta 2002 1586 190 198 11959460
  67. [78]Keller JN Hanni KB Markesbery WR Impaired proteasome function in Alzheimer’s disease J Neurochem 2000 75 436 439 doi: 10.1046/j.1471-4159.2000.0750436.x 10854289 · DOI · Paper page
  68. [79]Keller JN Schmitt FA Scheff SW Ding Q Chen Q Butterfield DA Markesbery WR Evidence of increased oxidative damage in subjects with mild cognitive impairment Neurology 2005 64 1152 1156 15824339
  69. [80]Korolainen MA Goldsteins G Alafuzoff I Koistinaho J Pirttila T Proteomic analysis of protein oxidation in Alzheimer’s disease brain Electrophoresis 2002 23 3428 3433 doi: 10.1002/1522-2683(200210)23:19<3428::AID-ELPS3428>3.0.CO;2-5 12373773 · DOI
  70. [81]Korolainen MA Goldsteins G Nyman TA Alafuzoff I Koistinaho J Pirttila T Oxidative modification of proteins in the frontal cortex of Alzheimer’s disease brain Neurobiol Aging 2006 27 42 53 doi: 10.1016/j.neurobiolaging.2004.11.010 16298240 · DOI
  71. [82]Lafon-Cazal M Fagni L Guiraud MJ Mary S Lerner-Natoli M Pin JP Shigemoto R Bockaert J mGluR7-like metabotropic glutamate receptors inhibit NMDA-mediated excitotoxicity in cultured mouse cerebellar granule neurons Eur J NeuroSci 1999 11 663 672 doi: 10.1046/j.1460-9568.1999.00475.x 10051767 · DOI
  72. [83]Lahiri DK Ge YW Maloney B Wavrant-De Vrieze F Hardy J Characterization of two APP gene promoter polymerphisms that appear to influence risk of late-onset Alzheimer’s disease Neurobiol Aging 2005 26 1329 1341 doi: 10.1016/j.neurobiolaging.2004.11.005 16243604 · DOI
  73. [85]Lauderback CM Hackett JM Huang FF Keller JN Szweda LI Markesbery WR Butterfield DA The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-non-enal in the Alzheimer’s disease brain: the role of Abeta 1–42 J Neurochem 2001 78 413 416 doi: 10.1046/j.1471-4159.2001.00451.x 11461977 · DOI · Paper page
  74. [86]Layfield R Fergusson J Aitken A Lowe J Landon M Mayer RJ Neurofibrillary tangles of Alzheimer’s disease brains contain 14-3-3 proteins Neurosci Lett 1996 209 57 60 doi: 10.1016/0304-3940(96)12598-2 8734909 · DOI
  75. [87]Levine RL Williams JA Stadtman ER Shacter E Carbonyl assays for determination of oxidatively modified proteins Methods Enzymol 1994 233 346 357 doi: 10.1016/S0076-6879(94)33040-9 8015469 · DOI
  76. [88]Levy-Lahad E Lahad A Wijsman EM Bird TD Schellenberg GD Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer’s disease Ann Neurol 1995 38 678 680 doi: 10.1002/ana.410380420 7574468 · DOI
  77. [89]Li X An WL Alafuzoff I Soininen H Winblad B Pei JJ Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain NeuroReport 2004 15 2237 2240 doi: 10.1097/00001756-200410050-00019 15371741 · DOI · Paper page
  78. [90]Ling M Merante F Chen HS Duff C Duncan AM Robinson BH The human mitochondrial elongation factor tu (EF-Tu) gene: cDNA sequence, genomic localization, genomic structure, and identification of a pseudogene Gene 1997 197 325 336 doi: 10.1016/S0378-1119(97)00279-5 9332382 · DOI
  79. [91]Link CD C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer’s disease Exp Gerontol 2006 41 1007 1013 doi: 10.1016/j.exger.2006.06.059 16930903 · DOI
  80. [92]Link CD Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans Proc Natl Acad Sci USA 1995 92 9368 9372 doi: 10.1073/pnas.92.20.9368 7568134 PMC40986 · DOI
  81. [93]Liou YC Sun A Ryo A Zhou XZ Yu ZX Huang HK Uchida T Bronson R Bing G Li X Hunter T Lu KP Role of the prolyl isomerase Pin1 in protecting against age-dependent neuro-degeneration Nature 2003 424 556 561 doi: 10.1038/nature01832 12891359 · DOI
  82. [94]Lledo PM Zhang X Sudhof TC Malenka RC Nicoll RA Postsynaptic membrane fusion and long-term potentiation Science 1998 279 399 403 doi: 10.1126/science.279.5349.399 9430593 · DOI · Paper page
  83. [95]Lovell MA Markesbery WR Oxidative damage in mild cognitive impairment and early Alzheimer’s disease J Neurosci Res 2007 85 3036 3040 doi: 10.1002/jnr.21346 17510979 · DOI
  84. [96]Lovell MA Markesbery WR Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid Arch Neurol 2001 58 392 396 doi: 10.1001/archneur.58.3.392 11255442 · DOI
  85. [97]Lovell MA Xie C Markesbery WR Acrolein is increased in Alzheimer’s disease brain and is toxic to primary hippocampal cultures Neurobiol Aging 2001 22 187 194 doi: 10.1016/S0197-4580(00)00235-9 11182468 · DOI
  86. [98]Lu KP Hanes SD Hunter T A human peptidyl-prolyl isomerase essential for regulation of mitosis Nature 1996 380 544 547 doi: 10.1038/380544a0 8606777 · DOI
  87. [99]Lubec G Nonaka M Krapfenbauer K Gratzer M Cairns N Fountoulakis M Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer’s disease brain is downregulated at the mRNA and dysregulated at the protein level J Neural Transm Suppl 1999 57 161 177 10666674
  88. [100]Marin R Ramirez CM Gonzalez M Gonzalez-Munoz E Zorzano A Camps M Alonso R Diaz M Voltage-dependent anion channel (VDAC) participates in amyloid beta-induced toxicity and interacts with plasma membrane estrogen receptor alpha in septal and hippocampal neurons Mol Membr Biol 2007 24 148 160 doi: 10.1080/09687860601055559 17453421 · DOI
  89. [101]Mark RJ Lovell MA Markesbery WR Uchida K Mattson MP A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide J Neurochem 1997 68 255 264 8978733
  90. [102]Markesbery WR Oxidative stress hypothesis in Alzheimer’s disease Free Radic Biol Med 1997 23 134 147 doi: 10.1016/S0891-5849(96)00629-6 9165306 · DOI · Paper page
  91. [104]Mattson MP Partin J Begley JG Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites Brain Res 1998 807 167 176 doi: 10.1016/S0006-8993(98)00763-X 9757026 · DOI
  92. [105]Mazzola JL Sirover MA Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer’s disease and in Huntington’s disease fibroblasts J Neurochem 2001 76 442 449 doi: 10.1046/j.1471-4159.2001.00033.x 11208907 · DOI
  93. [106]Meier-Rugez W Iwangoff P Reichlmeier K Neurochemical enzyme changes in Alzheimer’s and Pick’s disease Arch Gerontol Geriatr 1984 3 161 165 doi: 10.1016/0167-4943(84)90007-4 6089677 · DOI
  94. [107]Mello CF Sultana R Piroddi M Cai J Pierce WM Klein JB Butterfield DA Acrolein induces selective protein carbonylation in synaptosomes Neuroscience 2007 147 674 679 doi: 10.1016/j.neuroscience.2007.04.003 17570602 PMC1987324 · DOI
  95. [108]Milgram NW Head E Zicker SC Ikeda-Douglas CJ Murphey H Muggenburg B Siwak C Tapp D Cotman CW Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study Neurobiol Aging 2005 26 77 90 doi: 10.1016/j.neurobiolaging.2004.02.014 15585348 · DOI
  96. [109]Milgram NW Zicker SC Head E Muggenburg BA Murphey H Ikeda-Douglas CJ Cotman CW Dietary enrichment counteracts age-associated cognitive dysfunction in canines Neurobiol Aging 2002 23 737 745 doi: 10.1016/S0197-4580(02)00020-9 12392778 · DOI
  97. [110]Mohmmad Abdul H Butterfield DA Protection against amyloid beta-peptide (1–42)-induced loss of phospholipid asymmetry in synaptosomal membranes by tricyclodecan-9-xanthogenate (D609) and ferulic acid ethyl ester: implications for Alzheimer’s disease Biochim Biophys Acta 2005 1741 140 148 15955457
  98. [111]Mohmmad Abdul H Sultana R Keller JN St Clair DK Markesbery WR Butterfield DA Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1–42), HO and kainic acid: implications for Alzheimer’s disease J Neurochem 2006 96 1322 1335 doi: 10.1111/j.1471-4159.2005.03647.x 16478525 · DOI
  99. [112]Mohmmad Abdul H Wenk GL Gramling M Hauss-Wegrzyniak B Butterfield DA APP and PS-1 mutations induce brain oxidative stress independent of dietary cholesterol: implications for Alzheimer’s disease Neurosci Lett 2004 368 148 150 doi: 10.1016/j.neulet.2004.06.077 15351438 · DOI
  100. [113]Montine TJ Neely MD Quinn JF Beal MF Markesbery WR Roberts LJ Morrow JD Lipid peroxidation in aging brain and Alzheimer’s disease Free Radic Biol Med 2002 33 620 626 doi: 10.1016/S0891-5849(02)00807-9 12208348 · DOI
  101. [114]Morris JC Mild cognitive impairment and preclinical Alzheimer’s disease Geriatrics Suppl 2005 9 14 16025770
  102. [115]Munch G Thome J Foley P Schinzel R Riederer P Advanced glycation endproducts in ageing and Alzheimer’s disease Brain Res Brain Res Rev 1997 23 134 143 doi: 10.1016/S0165-0173(96)00016-1 9063589 · DOI
  103. [116]Murphy MP Beckett TL Ding Q Patel E Markesbery WR St Clair DK LeVine H 3rd Keller JN Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice Neurobiol Dis 2007 27 301 311 doi: 10.1016/j.nbd.2007.06.002 17651976 PMC13252904 · DOI
  104. [117]Murray IV Sindoni ME Axelsen PH Promotion of oxidative lipid membrane damage by amyloid beta proteins Biochemistry 2005 44 12606 12613 doi: 10.1021/bi050926p 16156673 PMC2288524 · DOI
  105. [118]Negash S Petersen LE Geda YE Knopman DS Boeve BF Smith GE Ivnik RJ Howard DV Howard JH Jr Petersen RC Effects of ApoE genotype and mild cognitive impairment on implicit learning Neurobiol Aging 2007 28 885 893 doi: 10.1016/j.neurobiolaging.2006.04.004 16701920 · DOI
  106. [120]Ojika K Hippocampal cholinergic neurostimulating peptide Seikagaku 1998 70 1175 1180 9796413
  107. [122]Pancholi V Multifunctional alpha-enolase: its role in diseases Cell Mol Life Sci 2001 58 902 920 doi: 10.1007/PL00000910 11497239 PMC11337373 · DOI
  108. [123]Parnetti L Palumbo B Cardinali L Loreti F Chionne F Cecchetti R Senin U Cerebrospinal fluid neuron-specific enolase in Alzheimer’s disease and vascular dementia Neurosci Lett 1995 183 43 45 doi: 10.1016/0304-3940(94)11110-5 7746484 · DOI
  109. [125]Perluigi M Fai Poon H Hensley K Pierce WM Klein JB Calabrese V De Marco C Butterfield DA Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice—a model of familial amyotrophic lateral sclerosis Free Radic Biol Med 2005 38 960 968 doi: 10.1016/j.freeradbiomed.2004.12.021 15749392 · DOI
  110. [126]Perluigi M Joshi G Sultana R Calabrese V De Marco C Coccia R Butterfield DA In vivo protection by the xanthate tricyclodecan-9-yl-xanthogenate against amyloid beta-peptide (1–42)-induced oxidative stress Neuroscience 2006 138 1161 1170 doi: 10.1016/j.neuroscience.2005.12.004 16427207 · DOI
  111. [128]Perluigi M Sultana R Cenini G Di Domenico F Memo M Pierce WM Coccia R Butterfield DA Redox proteomics identification of HNE-modified brain proteins in Alzheimers disease: Role of lipid peroxidation in AD pathogenesis Proteomics Clin Appli 2009 (Accepted) PMC2843938 20333275
  112. [129]Perry EK Curtis M Dick DJ Candy JM Atack JR Bloxham CA Blessed G Fairbairn A Tomlinson BE Perry RH Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease J Neurol Neurosurg Psychiatry 1985 48 413 421 doi: 10.1136/jnnp.48.5.413 3998751 PMC1028327 · DOI
  113. [130]Pestova TV Hellen CU The structure and function of initiation factors in eukaryotic protein synthesis Cell Mol Life Sci 2000 57 651 674 doi: 10.1007/PL00000726 11130464 PMC11147056 · DOI
  114. [132]Poon HF Farr SA Thongboonkerd V Lynn BC Banks WA Morley JE Klein JB Butterfield DA Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid: implications for aging and age-related neurodegenerative disorders Neurochem Int 2005 46 159 168 doi: 10.1016/j.neuint.2004.07.008 15627516 · DOI
  115. [133]Poon HF Shepherd HM Reed TT Calabrese V Stella AM Pennisi G Cai J Pierce WM Klein JB Butterfield DA Proteomics analysis provides insight into caloric restriction mediated oxidation and expression of brain proteins associated with age-related impaired cellular processes: Mitochondrial dysfunction, glutamate dysregulation and impaired protein synthesis Neurobiol Aging 2006 27 1020 1034 doi: 10.1016/j.neurobiolaging.2005.05.014 15996793 · DOI
  116. [134]Power JH Asad S Chataway TK Chegini F Manavis J Temlett JA Jensen PH Blumbergs PC Gai WP Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer’s disease pathology Acta Neuropathol 2008 115 611 622 doi: 10.1007/s00401-008-0373-3 18386021 PMC2386158 · DOI
  117. [135]Ralat LA Manevich Y Fisher AB Colman RF Direct evidence for the formation of a complex between 1-cysteine peroxiredoxin and glutathione S-transferase pi with activity changes in both enzymes Biochemistry 2006 45 360 372 doi: 10.1021/bi0520737 16401067 · DOI
  118. [136]Ramakers IH Visser PJ Aalten P Bekers O Sleegers K van Broeckhoven CL Jolles J Verhey FR The association between APOE genotype and memory dysfunction in subjects with mild cognitive impairment is related to age and Alzheimer pathology Dement Geriatr Cogn Disord 2008 26 101 108 doi: 10.1159/000144072 18617739 · DOI
  119. [137]Ramakrishnan P Dickson DW Davies P Pin1 colocalization with phosphorylated tau in Alzheimer’s disease and other tauopathies Neurobiol Dis 2003 14 251 264 doi: 10.1016/S0969-9961(03)00109-8 14572447 · DOI
  120. [139]Renes J de Vries EE Hooiveld GJ Krikken I Jansen PL Muller M Multidrug resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-hydroxynonenal Biochem J 2000 350 Pt 2 555 561 doi: 10.1042/0264-6021:3500555 10947971 PMC1221284 · DOI
  121. [140]Rinaldi P Polidori MC Metastasio A Mariani E Mattioli P Cherubini A Catani M Cecchetti R Senin U Mecocci P Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer’s disease Neurobiol Aging 2003 24 915 919 doi: 10.1016/S0197-4580(03)00031-9 12928050 · DOI
  122. [141]Sadik G Tanaka T Kato K Yamamori H Nessa BN Morihara T Takeda M Phosphorylation of tau at Ser214 mediates its interaction with 14-3-3 protein: implications for the mechanism of tau aggregation J Neurochem 2008 108 33 43 19014373
  123. [142]Santoni V Molloy M Rabilloud T Membrane proteins and proteomics: un amour impossible? Electrophoresis 2000 21 1054 1070 doi: 10.1002/(SICI)1522-2683(20000401)21:6<1054::AID-ELPS1054>3.0.CO;2-8 10786880 · DOI
  124. [143]Santpere G Puig B Ferrer I Oxidative damage of 14-3-3 zeta and gamma isoforms in Alzheimer’s disease and cerebral amyloid angiopathy Neuroscience 2007 146 1640 1651 doi: 10.1016/j.neuroscience.2007.03.013 17445990 · DOI
  125. [144]Selkoe DJ Alzheimer’s disease: genes, proteins, and therapy Physiol Rev 2001 81 741 766 11274343
  126. [145]Shimizu H Banno Y Sumi N Naganawa T Kitajima Y Nozawa Y Activation of p38 mitogen-activated protein kinase and caspases in UVB-induced apoptosis of human keratinocyte HaCaT cells J Invest Dermatol 1999 112 769 774 doi: 10.1046/j.1523-1747.1999.00582.x 10233770 · DOI
  127. [146]Sly WS Hu PY Human carbonic anhydrases and carbonic anhydrase deficiencies Annu Rev Biochem 1995 64 375 401 doi: 10.1146/annurev.bi.64.070195.002111 7574487 · DOI
  128. [147]Smith MA Richey Harris PL Sayre LM Beckman JS Perry G Widespread peroxynitrite-mediated damage in Alzheimer’s disease J Neurosci 1997 17 2653 2657 9092586 PMC6573097
  129. [148]Smith MA Richey PL Taneda S Kutty RK Sayre LM Monnier VM Perry G Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer’s disease Ann N Y Acad Sci 1994 738 447 454 7832455
  130. [150]Stadtman ER Berlett BS Reactive oxygen-mediated protein oxidation in aging and disease Chem Res Toxicol 1997 10 485 494 doi: 10.1021/tx960133r 9168245 · DOI
  131. [151]Stenbeck G Soluble NSF-attachment proteins Int J Biochem Cell Biol 1998 30 573 577 doi: 10.1016/S1357-2725(97)00064-2 9693958 · DOI
  132. [152]Subramaniam R Roediger F Jordan B Mattson MP Keller JN Waeg G Butterfield DA The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins J Neurochem 1997 69 1161 1169 9282939
  133. [153]Suh YH Checler F Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer’s disease Pharmacol Rev 2002 54 469 525 doi: 10.1124/pr.54.3.469 12223532 · DOI
  134. [154]Sultana R Boyd-Kimball D Poon HF Cai J Pierce WM Klein JB Markesbery WR Zhou XZ Lu KP Butterfield DA Oxidative modification and down-regulation of Pin1 in Alzheimer’s disease hippocampus: a redox proteomics analysis Neurobiol Aging 2006 27 918 925 doi: 10.1016/j.neurobiolaging.2005.05.005 15950321 · DOI
  135. [155]Sultana R Boyd-Kimball D Poon HF Cai J Pierce WM Klein JB Merchant M Markesbery WR Butterfield DA Redox proteomics identification of oxidized proteins in Alzheimer’s disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD Neurobiol Aging 2006 27 1564 1576 doi: 10.1016/j.neurobiolaging.2005.09.021 16271804 · DOI
  136. [156]Sultana R Butterfield DA Oxidatively modified GST and MRP1 in Alzheimer’s disease brain: implications for accumulation of reactive lipid peroxidation products Neurochem Res 2004 29 2215 2220 doi: 10.1007/s11064-004-7028-0 15672542 · DOI
  137. [157]Sultana R Newman S Mohmmad-Abdul H Keller JN Butterfield DA Protective effect of the xanthate, D609, on Alzheimer’s amyloid beta-peptide (1–42)-induced oxidative stress in primary neuronal cells Free Radic Res 2004 38 449 458 doi: 10.1080/1071576042000206478 15293552 · DOI
  138. [158]Sultana R Newman SF Abdul HM Cai J Pierce WM Klein JB Merchant M Butterfield DA Protective effect of D609 against amyloid-beta1–42-induced oxidative modification of neuronal proteins: redox proteomics study J Neurosci Res 2006 84 409 417 doi: 10.1002/jnr.20876 16634065 · DOI · Paper page
  139. [159]Sultana R Perluigi M Butterfield DA Redox proteomics identification of oxidatively modified proteins in Alzheimer’s disease brain and in vivo and in vitro models of AD centered around Abeta(1–42) J Chromatogr B Analyt Technol Biomed Life Sci 2006 833 3 11 doi: 10.1016/j.jchromb.2005.09.024 16236561 · DOI
  140. [160]Sultana R Piroddi M Galli F Butterfield DA Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment Neurochem Res 2008 33 2540 2546 doi: 10.1007/s11064-008-9593-0 18320305 · DOI
  141. [161]Sultana R Poon HF Cai J Pierce WM Merchant M Klein JB Markesbery WR Butterfield DA Identification of nitrated proteins in Alzheimer’s disease brain using a redox proteomics approach Neurobiol Dis 2006 22 76 87 doi: 10.1016/j.nbd.2005.10.004 16378731 · DOI · Paper page
  142. [162]Sultana R Ravagna A Mohmmad-Abdul H Calabrese V Butterfield DA Ferulic acid ethyl ester protects neurons against amyloid beta- peptide(1–42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity J Neurochem 2005 92 749 758 doi: 10.1111/j.1471-4159.2004.02899.x 15686476 · DOI
  143. [163]Sultana R Reed T Perluigi M Coccia R Pierce WM Butterfield DA Proteomic Identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study J Cell Mol Med 2007 11 839 851 doi: 10.1111/j.1582-4934.2007.00065.x 17760844 PMC3823261 · DOI · Paper page
  144. [164]Tamagno E Parola M Guglielmotto M Santoro G Bardini P Marra L Tabaton M Danni O Multiple signaling events in amyloid beta-induced, oxidative stress-dependent neuronal apoptosis Free Radic Biol Med 2003 35 45 58 doi: 10.1016/S0891-5849(03)00244-2 12826255 · DOI
  145. [165]Tamagno E Robino G Obbili A Bardini P Aragno M Parola M Danni O H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK Exp Neurol 2003 180 144 155 doi: 10.1016/S0014-4886(02)00059-6 12684028 · DOI
  146. [166]Tchaikovskaya T Fraifeld V Urphanishvili T Andorfer JH Davies P Listowsky I Glutathione S-transferase hGSTM3 and ageing-associated neurodegeneration: relationship to Alzheimer’s disease Mech Ageing Dev 2005 126 309 315 doi: 10.1016/j.mad.2004.08.029 15621212 · DOI
  147. [167]Terry RD Masliah E Salmon DP Butters N DeTeresa R Hill R Hansen LA Katzman R Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment Ann Neurol 1991 30 572 580 doi: 10.1002/ana.410300410 1789684 · DOI · Paper page
  148. [168]Thompson J Dahlberg AE Testing the conservation of the translational machinery over evolution in diverse environments: assaying Thermus thermophilus ribosomes and initiation factors in a coupled transcription-translation system from Escherichia coli Nucleic Acids Res 2004 32 5954 5961 doi: 10.1093/nar/gkh925 15534366 PMC528807 · DOI
  149. [169]Tremblay C Pilote M Phivilay A Emond V Bennett DA Calon F Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer’s disease J Alzheimers Dis 2007 12 377 390 18198424
  150. [170]Uchida K Stadtman ER Modification of histidine residues in proteins by reaction with 4-hydroxynonenal Proc Natl Acad Sci USA 1992 89 4544 4548 doi: 10.1073/pnas.89.10.4544 1584790 PMC49119 · DOI
  151. [171]Viola KL Velasco PT Klein WL Why Alzheimer’s is a disease of memory: the attack on synapses by A beta oligomers (ADDLs) J Nutr Health Aging 2008 12 51S 57S doi: 10.1007/BF02982587 18165846 · DOI
  152. [173]Walsh DM Klyubin I Fadeeva JV Rowan MJ Selkoe DJ Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition Biochem Soc Trans 2002 30 552 557 doi: 10.1042/BST0300552 12196135 · DOI
  153. [174]Watson GS Craft S Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer’s disease Eur J Pharmacol 2004 490 97 113 doi: 10.1016/j.ejphar.2004.02.048 15094077 · DOI · Paper page
  154. [175]Wevers A Witter B Moser N Burghaus L Banerjee C Steinlein OK Schutz U de Vos RA Steur EN Lindstrom J Schroder H Classical Alzheimer features and cholinergic dysfunction: towards a unifying hypothesis? Acta Neurol Scand Suppl 2000 176 42 48 doi: 10.1034/j.1600-0404.2000.00306.x 11261804 · DOI
  155. [176]Whitehouse PJ Price DL Clark AW Coyle JT DeLong MR Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis Ann Neurol 1981 10 122 126 doi: 10.1002/ana.410100203 7283399 · DOI · Paper page
  156. [177]Williams TI Lynn BC Markesbery WR Lovell MA Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer’s disease Neurobiol Aging 2006 27 1094 1099 doi: 10.1016/j.neurobiolaging.2005.06.004 15993986 · DOI
  157. [178]Yatin SM Varadarajan S Butterfield DA Vitamin E prevents Alzheimer’s amyloid beta-peptide (1–42)-induced neuronal protein oxidation and reactive oxygen species production J Alzheimers Dis 2000 2 123 131 12214102
  158. [180]Zarkovic K 4-hydroxynonenal and neurodegenerative diseases Mol Aspects Med 2003 24 293 303 doi: 10.1016/S0098-2997(03)00024-4 12893007 · DOI
  159. [181]Zhou XZ Kops O Werner A Lu PJ Shen M Stoller G Kullertz G Stark M Fischer G Lu KP Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins Mol Cell 2000 6 873 883 doi: 10.1016/S1097-2765(05)00083-3 11090625 · DOI

Cited by

Sorted by citations

Authors
Sultana, R., Perluigi, M., & Butterfield, D. A.
Affiliations
University of Kentucky (US)
Corresponding author
Butterfield, D. Allan
ORCID
Butterfield, D. Allan
Venue
Acta Neuropathologica
Publisher
Springer Science and Business Media LLC
Published
2009-03-14
Volume
118
Issue
1
Pages
131-150
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
DOI
10.1007/s00401-009-0517-0
PMC
PMC2818870
OpenAlex
W1970259736
Cited by
215
References
22
Citations by year
2026: 9 · 2025: 10 · 2024: 10 · 2023: 12 · 2022: 11 · 2021: 9 · 2020: 14 · 2019: 5 · 2018: 10 · 2017: 8 · 2016: 8 · 2015: 9 · 2014: 14 · 2013: 14 · 2012: 17
FWCI
2.59
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Acta Neuropathologica (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Funders
National Institute on Aging (P01AG010836, P01AG005119, R01AG029839, AG029839, AG 10836, AG0 5119)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
Keywords
Alzheimer's disease, mild cognitive impairment, amyloid-beta, oxidative stress, oxidized proteins, redox proteomics, AD pathogenesis, animal models of Alzheimer's disease, synaptic loss, amyloid plaques, neurofibrillary tangles, energy metabolism, protein degradation, synaptic function, long-term potentiation, early disease markers
MeSH terms
Alzheimer Disease, Animals, Brain, Cognition Disorders, Disease Models, Animal, Humans, Oxidation-Reduction, Amyloid beta-Peptides, Oxidative Stress, Proteomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review